For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Mereo Biopharma Group Plc ADR (NASDAQ: MREO) was $3.45 for the day, down -7.75% from the previous closing price of $3.74. In other words, the price has decreased by -$7.75 from its previous closing price. On the day, 2.53 million shares were traded. MREO stock price reached its highest trading level at $3.82 during the session, while it also had its lowest trading level at $3.26.
Ratios:
Our analysis of MREO’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 6.10 and its Current Ratio is at 6.10. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on December 06, 2024, initiated with a Buy rating and assigned the stock a target price of $7.
On June 13, 2024, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $8.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 13 ’24 when Scots-Knight Denise sold 60,046 shares for $4.22 per share. The transaction valued at 253,454 led to the insider holds 808,921 shares of the business.
Scots-Knight Denise sold 28,611 shares of MREO for $127,968 on Sep 12 ’24. The Chief Executive Officer now owns 868,967 shares after completing the transaction at $4.47 per share. On Sep 13 ’24, another insider, Lewicki John A., who serves as the Chief Scientific Officer of the company, sold 10,937 shares for $4.22 each. As a result, the insider received 46,165 and left with 78,630 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MREO now has a Market Capitalization of 535253696 and an Enterprise Value of 2602420736. Its current Enterprise Value per Revenue stands at 2602.421 whereas that against EBITDA is -69.442.
Stock Price History:
Over the past 52 weeks, MREO has reached a high of $5.02, while it has fallen to a 52-week low of $1.97. The 50-Day Moving Average of the stock is -13.37%, while the 200-Day Moving Average is calculated to be -7.71%.
Shares Statistics:
MREO traded an average of 746.22K shares per day over the past three months and 676470 shares per day over the past ten days. A total of 154.73M shares are outstanding, with a floating share count of 137.43M. Insiders hold about 11.19% of the company’s shares, while institutions hold 59.44% stake in the company. Shares short for MREO as of 1732838400 were 6631324 with a Short Ratio of 8.89, compared to 1730332800 on 4565429. Therefore, it implies a Short% of Shares Outstanding of 6631324 and a Short% of Float of 5.06.
